# CHIMERA: HCP commentary report

> 22 verified statements (0 from clinicians verified by NPI or staff page) from 6 commentary sources · 4 findings · updated Oct 31, 2026

## Report

- Trial: Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
- NCT ID: NCT06155279
- Registry: https://clinicaltrials.gov/study/NCT06155279
- Sponsor: Istituto Oncologico Veneto IRCCS
- Phase: Phase 2
- Status: Active, not recruiting
- Drugs tested: pembrolizumab plus pemetrexed plus platinum-based chemotherapy
- Indication: resectable epithelioid and biphasic pleural mesothelioma
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: a3834a939da718c950197bb356142530b66783ff5095315fffca7abcd912cb15

## Counts

- HCP commentary sources screened: 69
- Sources cited by verified statements: 7
- Verified statements: 22
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 0
- Findings: 4
- Named people in screened sources (unnamed speakers and accounts not counted): 1
- Voices cited: 1
- Cited voices identity-verified: 0
- Organisational or shared accounts (not counted as people): 3

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

CHIMERA asks whether pembrolizumab plus platinum–pemetrexed before surgery produces pathological complete responses in resectable epithelioid or biphasic pleural mesothelioma. Commentary comes from YouTube, a podcast and X posts, including an interviewee described in the sources as presenting CHIMERA and as a principal investigator. Discussion centers on that speaker’s interest in major pathological response despite a negative primary-endpoint assessment, and on the unresolved question of which patients might benefit from the regimen.

## Open Medical Affairs question

How should the MPR signal be discussed without implying a positive primary endpoint or an identified benefiting subgroup?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Interest in MPR does not reverse the negative primary endpoint
- F2. Response heterogeneity leaves the benefiting population unresolved
- F3. Centralized surgery is a distinctive feature of a speaker's account
- F4. A public-facing account expresses enthusiasm as a question, not a benefit claim

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 11 | 4 | 4 | 1 | none recorded | 3 |
| F2 | 3 | 3 | 3 | 1 | none recorded | 2 |
| F3 | 5 | 3 | 3 | 1 | none recorded | 2 |
| F4 | 1 | 1 | 1 | 1 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 4 | 0 | 0 | 0 | 7 | 12 | 2 | 1 post or article, 2 podcasts and video, 1 registry | yes |
| F2 | 3 | 0 | 0 | 0 | 0 | 3 | 1 | 1 post or article, 2 podcasts and video | yes |
| F3 | 3 | 0 | 0 | 0 | 2 | 5 | 1 | 1 post or article, 2 podcasts and video | yes |
| F4 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 post or article | no |

### Trial dimensions

- Primary endpoint: Primary endpoint - To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR): F1 (6 shared claims)
- Secondary endpoints: F1 (2 shared claims)
- Population and setting: F1 (2 shared claims), F3 (2 shared claims)
- The comparison: F1 (4 shared claims), F3 (2 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F1 (3 shared claims), F3 (4 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 22 | Paid |
| Trial aspects mapped | 8 | Free |
| Sources with links | 7 | Counts free |
| Speaker attribution for cited voices | 1 | Paid |

## Trial aspects

7 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Primary endpoint - To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR) | discussed | 6 | 2 |
| Secondary endpoints | discussed | 2 | 2 |
| Population and setting | discussed | 2 | 2 |
| The comparison | discussed | 5 | 2 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 4 | 2 |
| Residual-tumor heterogeneity and translational patient selection | discussed | 2 | 2 |
| Public-facing enthusiasm and the open question of outcome benefit | discussed | 1 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 29 | 4 |
| YouTube | 20 | 1 |
| Podcasts | 10 | 1 |
| Bluesky threads | 10 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2023-11-20 to 2026-10-27
- Cited window: 2026-07-28 to 2026-10-27
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
- Registry: NCT06155279 (https://clinicaltrials.gov/study/NCT06155279)
- Study IDs: IOV-Me-01-2023-CHIMERA
- Sponsor: Istituto Oncologico Veneto IRCCS
- Collaborators: MSD Italia S.r.l.
- Design: Phase 2 · interventional, na, single group, phase2
- Status: Active, not recruiting
- Enrollment: 41 (actual)
- Start: 2024-11-06 (actual)
- Primary completion: 2025-12-22 (actual)
- Primary endpoint: Primary endpoint - To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR) (Pathological complete response will be evaluated following neoadjuvant treatment and within 6 weeks after the last dose of study intervention.)
- Intervention: Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 5 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 3 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The named clinical interpretation comes from a speaker. The video, podcast account and publisher summaries should not be counted as independent HCP agreement.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Some other videos considered for this edition lacked fully checked speaker-by-speaker transcripts, limiting coverage beyond the named account summarized here.
- No separate full protocol, exact-trial results publication or exact regulatory label for the complete regimen was identified in the reviewed materials. Registry methods and interview reporting cannot resolve all result-denominator questions or establish regulatory status.
- The podcast transcript contains an enrollment discrepancy, while the video account reports 41 enrolled patients. No reconciliation is available.
- No substantive safety or tolerability assessment, survival interpretation or completed predictive patient-selection result was identified in the assessed statements. These absences are not evidence of safety, lack of survival benefit or absence of a benefiting subgroup.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition, corrected 2026-10-31
  - Correction 2026-10-31: Corrected to match the delivered report: the report description. The trial's name is spelled as its investigators write it, “CHIMERA” (NCT06155279), outside quotations (was “Chimera”, “ChimeraX”).

Last checked for new commentary 2026-10-31. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (22 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (0 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/chimera-nct06155279
- Agents: POST https://www.erudio.com/api/orders with {"report": "chimera-nct06155279", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=chimera-06155279

## Cite

Erudio Health. CHIMERA (NCT06155279): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/chimera-nct06155279

## Machine access

- JSON: https://www.erudio.com/reports/chimera-nct06155279.json
- Markdown: https://www.erudio.com/reports/chimera-nct06155279.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "chimera-06155279"}`